Xenetic Biosciences
XBIO
4 hedge funds and large institutions have $902K invested in Xenetic Biosciences in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
0% less ownership
Funds ownership: 0.03% → 0.03% (-0%)
40% less capital invested
Capital invested by funds: $1.51M → $902K (-$604K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$13.6K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Royal Bank of Canada
Toronto,
Ontario, Canada
| $894K | – | – | – |
|
|
2
Morgan Stanley
New York
| $6K | -$13.6K | -32 | -65% |
|
|
OIA
3
OneDigital Investment Advisors
Overland Park,
Kansas
| $1K | +$1.71K | +4 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $1K | +$1.71K | +4 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| – | -$5K | -8 | Closed |
|
XBIO Hedge Fund Activity: Q2 2017 in Review
4 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q2 2017, worth a combined $902K — down 40% from $1.51M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new XBIO positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $1.71K. The largest seller was Morgan Stanley, cutting an estimated $13.6K.
- 4 institutional investors held Xenetic Biosciences (XBIO) as of Q2 2017, up from 3 in Q1 2017.
- Funds reported $902K of Xenetic Biosciences stock for Q2 2017, down 40% quarter-over-quarter.
- 2 funds opened new Xenetic Biosciences positions in Q2 2017 and 1 closed out, a net change of +1 holder.
- The largest Xenetic Biosciences buyer in Q2 2017 was UBS Group, an estimated $1.71K added.
- The largest Xenetic Biosciences seller in Q2 2017 was Morgan Stanley, an estimated $13.6K sold.
Based on aggregated 13F filings for Q2 2017.